|
Drug Category |
Description |
Drug Name and Drug Sponsor |
FDA Status |
|
Interferons |
Fusion protein Interferon alfa-albumin |
Albuferon
(Human Genome Sciences) |
Phase
II |
|
Purified multi-subtype human IFN alfa |
Multiferon
(Viragen) |
Phase
II |
|
Pegylated alfacon-1 |
Peg-alfacon
(InterMune) |
Phase
1 |
|
Interferon omega |
Omega interferon
(Biomedicines) |
Phase
I |
|
Medusa interferon |
Medusa Interferon
(Flamel
Technologies) |
Phase
II |
|
Interferon beta-1a |
Rebif
(Ares Serono) |
Phase
III |
|
Oral
interferon alfa |
Oral interferon alfa
(Amarillo
Biosciences) |
Phase
I |
|
Ribavirin Alternatives |
Amidine prodrug of
ribavirin
(nucleoside analogue) |
Viramidine
(Valeant
Pharmaceuticals) |
Phase
3 |
|
IMPDH
inhibitors |
Merimepodib [VX-497]
(Vertex
Pharmaceuticals) |
Phase
2 |
|
Mycophenolic acid |
Mycophenolic acid
(Roche Pharmaceuticals) |
Phase
1 |
|
Antiviral |
Amantadine
(Endo Labs, etc) |
Phase
3 |
|
Immunomodulators |
Augmented T-cell function |
Thymosin alfa-1 [Zadaxin]
(Sci-Clone) |
Phase
3 |
|
Enhanced IFN activation of T and natural killer cells |
Histamine dihydrochloride
(Ceplene)
(Maxim Pharmaceuticals) |
Phase
2 |
Therapeutic vaccine
(viral E1 protein of HCV) |
E1 vaccine
(Innogenetics) |
Phase
2 |
|
Therapeutic vaccine |
IC-41
(Intercell) |
Phase
2 |
|
Vaccine |
HCV-MF59
(Chiron) |
Phase
1 |
|
Inhibitors of Viral Enzymes |
synthetic
oligonucleotide and selective
TLR9
agonist |
Actilon
(Coley) |
Phase
1/2 |
|
NS3
serine protease inhibitor |
BILN-2061
(Boehringer
Ingelheim) |
Phase
2
(on hold) |
|
Serine protease inhibitor |
Sch-6
(Schering-Plough) |
Phase
1 |
|
NS3-4A protease inhibitor |
VX-950
(Vertex Pharmaceuticals) |
Phase
2 |
|
RdRp
inhibitor |
Valopicitabine [NM-283]
(Idenix
Pharmaceuticals) |
Phase
1/2 |
|
Polymerase inhibitor |
JDK-003
(Akros
Pharmaceuticals) |
Phase
1 |
|
Polymerase inhibitor |
HCV-896
(ViriPharma) |
Phase
1 |
|
Antifibrotics |
Antisense
oligonucleotide |
ISIS-14803
(Isis Pharmaceuticals) |
Phase
2 |
|
Anti-tumor necrosis factor α (FDA-approved for treatment of
arthritis) |
Enbrel
(Wyeth-Ayerst) |
Phase
1 |
|
Oral
phospholipid antifibrotics |
IP-501
(Indevus Pharmaceuticals) |
Phase
3 |
|
Others |
Caspase inhibitors |
ID-6556
(Idun Pharmaceuticals) |
Phase
2 |
|
Anti-CD20 mononclonal antibody |
Rituximab
(Genentech) |
Phase
1/2 |
|
Monoclonal antibody |
XLT-6865
(XTL) |
Phase
1/2 |
|
Prodrug of isatoribine |
ANA-971
(Anadys) |
Phase
1 |
|
Prodrug of isatoribine |
ANA-245
(Anadys) |
Phase
1/2 |
|
Anti-phospholipid |
Tarvacin
(Peregrine) |
Phase
1 |
